Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Tacrolimus 500micrograms/5ml oral suspension
0802020T0AAARAR
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacrolimus 5mg/1ml solution for infusion ampoules
0802020T0AAACAC
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacrolimus 750microgram modified-release tablets
0802020T0AABDBD
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacrolimus 800micrograms/5ml oral solution
0802020T0AABABA
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacrolimus 900micrograms/5ml oral suspension
0802020T0AABBBB
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tafinlar 50mg capsules
0801050CUBBAAAA
|
Tafinlar | Dabrafenib | Malignant Disease and Immunosuppression | No data available |
|
Tafinlar 75mg capsules
0801050CUBBABAB
|
Tafinlar | Dabrafenib | Malignant Disease and Immunosuppression | No data available |
|
Tagrisso 40mg tablets
0801050CGBBAAAA
|
Tagrisso | Osimertinib | Malignant Disease and Immunosuppression | No data available |
|
Tagrisso 80mg tablets
0801050CGBBABAB
|
Tagrisso | Osimertinib | Malignant Disease and Immunosuppression | No data available |
|
Tamofen 10 tablets
0803041S0BFAAAA
|
Tamofen | Tamoxifen citrate | Malignant Disease and Immunosuppression | No data available |
|
Tamofen 20 tablets
0803041S0BFABAB
|
Tamofen | Tamoxifen citrate | Malignant Disease and Immunosuppression | No data available |
|
Tamofen 40 tablets
0803041S0BFACAC
|
Tamofen | Tamoxifen citrate | Malignant Disease and Immunosuppression | No data available |
|
Tamoxifen 10mg/5ml oral liquid
0803041S0AAAHAH
|
Tamoxifen citrate | Tamoxifen citrate | Malignant Disease and Immunosuppression | No data available |
|
Tamoxifen 20mg/5ml oral liquid
0803041S0AAAGAG
|
Tamoxifen citrate | Tamoxifen citrate | Malignant Disease and Immunosuppression | No data available |
|
Tamoxifen 40mg/5ml oral liquid
0803041S0AAAIAI
|
Tamoxifen citrate | Tamoxifen citrate | Malignant Disease and Immunosuppression | No data available |
|
Tarceva 100mg tablets
0801050AEBBAAAA
|
Tarceva | Erlotinib | Malignant Disease and Immunosuppression | No data available |
|
Tarceva 150mg tablets
0801050AEBBABAB
|
Tarceva | Erlotinib | Malignant Disease and Immunosuppression | No data available |
|
Tarceva 25mg tablets
0801050AEBBACAC
|
Tarceva | Erlotinib | Malignant Disease and Immunosuppression | No data available |
|
Targretin 75mg capsules
0801050ABBBAAAA
|
Targretin | Bexarotene | Malignant Disease and Immunosuppression | No data available |
|
Tasigna 150mg capsules
0801050ASBBABAB
|
Tasigna | Nilotinib | Malignant Disease and Immunosuppression | No data available |
|
Tasigna 200mg capsules
0801050ASBBAAAA
|
Tasigna | Nilotinib | Malignant Disease and Immunosuppression | No data available |
|
Tasigna 50mg capsules
0801050ASBBACAC
|
Tasigna | Nilotinib | Malignant Disease and Immunosuppression | No data available |
|
Taxceus 140mg/7ml concentrate for inf vials
0801050D0BCACAH
|
Taxceus | Docetaxel | Malignant Disease and Immunosuppression | No data available |
|
Taxceus 20mg/1ml concentrate for solution for infusion vials
0801050D0BCAAAC
|
Taxceus | Docetaxel | Malignant Disease and Immunosuppression | No data available |
|
Taxceus 80mg/4ml concentrate for solution for infusion vials
0801050D0BCABAD
|
Taxceus | Docetaxel | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.